Tolfenamic acid suppresses cytochrome P450 2E1 expression in mouse liver

Integrative Biology (United Kingdom)

Volumn 4, Issue 9, 2012, Pages 1122-1129

  Siddiqi, Shadab A ^b   Shukoor, Mohammed I ^a   Tiwari, Samata ^b   Sankpal, Umesh T ^a   Maliakal, Pius ^a,c   Connelly, Sarah F ^a   Siddiqi, Shaila ^b   Basha, Riyaz ^a,b,c  

^a M D ANDERSON CANCER CENTER ORLANDO   (United States)

^b UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^c FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORN OIL; CYTOCHROME P450 2E1; N BENZYL N METHYLNITROSAMINE; TOLFENAMIC ACID; TRANSCRIPTION FACTOR SP;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FRACTIONATION; CELL LYSATE; CELL VIABILITY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; FEMALE; LIVER; LIVER CARCINOGENESIS; LIVER CELL; LIVER MICROSOME; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TREATMENT DURATION; WESTERN BLOTTING;

EID: 84870903300     PISSN: 17579694     EISSN: 17579708     Source Type: Journal    
DOI: 10.1039/c2ib20127e     Document Type: Article

References (76)

1. T. N. Walsh N. Noonan D. Hollywood A. Kelly N. Keeling T. P. Hennessy A comparison of multimodal therapy and surgery for esophageal adenocarcinoma N. Engl. J. Med. 1996 335 7 462 467
2. D. M. Parkin F. I. Bray S. S. Devesa Cancer burden in the year 2000. The global picture Eur. J. Cancer 2001 37 Suppl 8 S4 S66
3. G. D. Stoner L. S. Wang T. Chen Chemoprevention of esophageal squamous cell carcinoma Toxicol. Appl. Pharmacol. 2007 224 3 337 349
4. G. D. Stoner A. Gupta Etiology and chemoprevention of esophageal squamous cell carcinoma Carcinogenesis 2001 22 11 1737 1746
5. E. L. Wynder I. J. Bross A study of etiological factors in cancer of the esophagus Cancer 1961 14 389 413
6. S. S. Hecht and G. D. Stoner, Lung and esophageal carcinogenesis, Williams and Wilkins, Baltimore, MD, 1996, pp. 25-50
7. M. H. Li C. Ji S. J. Cheng Occurrence of nitroso compounds in fungi-contaminated foods: a review Nutr. cancer 1986 8 1 63 69
8. U. Ribeiro, Jr. M. C. Posner A. V. Safatle-Ribeiro J. C. Reynolds Risk factors for squamous cell carcinoma of the oesophagus Br. J. Surg. 1996 83 9 1174 1185
9. G. D. Stoner H. Qin T. Chen P. S. Carlton M. E. Rose R. M. Aziz R. Dixit The effects of L-748706, a selective cyclooxygenase-2 inhibitor, on N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis Carcinogenesis 2005 26 9 1590 1595
10. T. Baden K. Yamamichi T. Michiura A. Tsubura K. Hioki Sequential endoscopic findings and histological changes of N-nitrosomethylbenzylamine- induced esophageal carcinogenesis in rats Oncol. Rep. 2006 16 5 965 970
11. T. Chen M. E. Rose H. Hwang R. G. Nines G. D. Stoner Black raspberries inhibit N-nitrosomethylbenzylamine (NMBA)-induced angiogenesis in rat esophagus parallel to the suppression of COX-2 and iNOS Carcinogenesis 2006 27 11 2301 2307
12. J. G. de Boer H. Yang J. Holcroft K. Skov Chemoprotection against N-nitrosomethylbenzylamine-induced mutation in the rat esophagus Nutr. cancer 2004 50 2 168 173
13. Z. Li Y. Shimada A. Kawabe F. Sato M. Maeda I. Komoto T. Hong Y. Ding J. Kaganoi M. Imamura Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by JTE-522, a selective COX-2 inhibitor Carcinogenesis 2001 22 4 547 551
14. L. W. Wattenberg Chemoprevention of cancer Cancer Res. 1985 45 1 1 8
15. G. D. Stoner L. S. Wang T. Chen Chemoprevention of esophageal squamous cell carcinoma Toxicol. Appl. pharmacol. 2007 224 3 337 349
16. M. J. Wargovich C. Woods V. W. Eng L. C. Stephens K. Gray Chemoprevention of N-nitrosomethylbenzylamine-induced esophageal cancer in rats by the naturally occurring thioether, diallyl sulfide Cancer Res. 1988 48 23 6872 6875
17. S. Mandal G. D. Stoner Inhibition of N-nitrosobenzylmethylamine-induced esophageal tumorigenesis in rats by ellagic acid Carcinogenesis 1990 11 1 55 61
18. Y. Mori K. Tatematsu A. Koide S. Sugie T. Tanaka H. Mori Modification by curcumin of mutagenic activation of carcinogenic N-nitrosamines by extrahepatic cytochromes P-450 2B1 and 2E1 in rats Cancer sci. 2006 97 9 896 904
19. J. T. Wilkinson M. A. Morse L. A. Kresty G. D. Stoner Effect of alkyl chain length on inhibition of N-nitrosomethylbenzylamine-induced esophageal tumorigenesis and DNA methylation by isothiocyanates Carcinogenesis 1995 16 5 1011 1015
20. Z. Y. Wang L. D. Wang M. J. Lee C. T. Ho M. T. Huang A. H. Conney C. S. Yang Inhibition of N-nitrosomethylbenzylamine-induced esophageal tumorigenesis in rats by green and black tea Carcinogenesis 1995 16 9 2143 2148
21. Z. G. Li T. Hong Y. Shimada I. Komoto A. Kawabe Y. Ding J. Kaganoi Y. Hashimoto M. Imamura Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol Carcinogenesis 2002 23 9 1531 1536
22. T. Chen R. G. Nines S. M. Peschke L. A. Kresty G. D. Stoner Chemopreventive effects of a selective nitric oxide synthase inhibitor on carcinogen-induced rat esophageal tumorigenesis Cancer Res. 2004 64 10 3714 3717
23. P. J. Rijken W. G. Timmer A. J. van de Kooij I. M. van Benschop S. A. Wiseman M. Meijers L. B. Tijburg Effect of vegetable and carotenoid consumption on aberrant crypt multiplicity, a surrogate end-point marker for colorectal cancer in azoxymethane-induced rats Carcinogenesis 1999 20 12 2267 2272
24. T. Narisawa Y. Fukaura M. Hasebe S. Nomura S. Oshima T. Inakuma Prevention of N-methylnitrosourea-induced colon carcinogenesis in rats by oxygenated carotenoid capsanthin and capsanthin-rich paprika juice Proc. Soc. Exp. Biol. Med. 2000 224 2 116 122
25. E. Okajima M. Tsutsumi S. Ozono H. Akai A. Denda H. Nishino S. Oshima H. Sakamoto Y. Konishi Inhibitory effect of tomato juice on rat urinary bladder carcinogenesis after N-butyl-N-(4-hydroxybutyl)nitrosamine initiation Jpn. J. Cancer Res. 1998 89 1 22 26
26. W. J. Blot J. Y. Li P. R. Taylor W. Guo S. Dawsey G. Q. Wang C. S. Yang S. F. Zheng M. Gail G. Y. Li et al., Nutrition intervention trials in Linxian, China: supplementation with specific vitamin-mineral combinations, cancer incidence, and disease-specific mortality in the general population J. Natl. Cancer Inst. 1993 85 18 1483 1492
27. J. Y. Li P. R. Taylor B. Li S. Dawsey G. Q. Wang A. G. Ershow W. Guo S. F. Liu C. S. Yang Q. Shen et al., Nutrition intervention trials in Linxian, China: multiple vitamin-mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia J. Natl. Cancer Inst. 1993 85 18 1492 1498
28. D. G. Beer G. D. Stoner Clinical models of chemoprevention for the esophagus Hematol. Oncol. Clin. N. Am. 1998 12 5 1055 1077
29. T. Hampton NSAID studies abound in cancer research: drugs may have niche in prevention and treatment JAMA, J. Am. Med. Assoc. 2005 293 21 2579 2580
30. M. A. Altinoz R. Korkmaz NF-kappaB, macrophage migration inhibitory factor and cyclooxygenase-inhibitions as likely mechanisms behind the acetaminophen- and NSAID-prevention of the ovarian cancer Neoplasma 2004 51 4 239 247
31. T. L. Vaughan L. M. Dong P. L. Blount K. Ayub R. D. Odze C. A. Sanchez P. S. Rabinovitch B. J. Reid Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study Lancet Oncol. 2005 6 12 945 952
32. C. V. Rao B. S. Reddy NSAIDs and chemoprevention Curr. Cancer Drug Targets 2004 4 1 29 42
33. D. A. Corley K. Kerlikowske R. Verma P. Buffler Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis Gastroenterology 2003 124 1 47 56
34. M. Abdelrahim C. H. Baker J. L. Abbruzzese S. Safe Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation J. Natl. Cancer Inst. 2006 98 12 855 868
35. R. Basha S. B. Ingersoll U. T. Sankpal S. Ahmad C. H. Baker J. R. Edwards R. W. Holloway S. Kaja M. Abdelrahim Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors Gynecol. Oncol. 2011 122 1 163 170
36. D. Eslin U. T. Sankpal C. Lee R. M. Sutphin P. Maliakal E. Currier G. Sholler M. Khan R. Basha Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: A novel therapeutic agent for neuroblastoma Mol. Carcinog. 2011 10.1002/mc.21866
37. S. Konduri J. Colon C. H. Baker S. Safe J. L. Abbruzzese A. Abudayyeh M. R. Basha M. Abdelrahim Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression Mol. Cancer Ther. 2009 8 3 533 542
38. U. T. Sankpal M. Abdelrahim S. F. Connelly C. M. Lee R. Madero-Visbal J. Colon J. Smith S. Safe P. Maliakal R. Basha Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer Prostate 2012 10.1002/pros.22518
39. P. Maliakal M. Abdelrahim U. T. Sankpal C. Maliakal C. H. Baker S. Safe L. J. Herrera A. Abudayyeh S. Kaja R. Basha Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats Invest. New Drugs 2012 30 3 853 861
40. D. W. Nebert T. P. Dalton The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis Nat. Rev. Cancer 2006 6 12 947 960
41. C. Rodriguez-Antona M. Ingelman-Sundberg Cytochrome P450 pharmacogenetics and cancer Oncogene 2006 25 11 1679 1691
42. P. Jancova P. Anzenbacher E. Anzenbacherova Phase II drug metabolizing enzymes Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2010 154 2 103 116
43. A. Gonzalez-Garcia L. R-Borlado E. Leonardo I. Merida A. C. Martinez A. C. Carrera Lck is necessary and sufficient for Fas-ligand expression and apoptotic cell death in mature cycling T cells J. Immunol. 1997 158 9 4104 4112
44. F. P. Guengerich D. H. Kim M. Iwasaki Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects Chem. Res. Toxicol. 1991 4 2 168 179
45. Y. Mori A. Koide Y. Kobayashi K. Morimura M. Kaneko S. Fukushima Effect of ethanol treatment on metabolic activation and detoxification of esophagus carcinogenic N-nitrosamines in rat liver Mutagenesis 2002 17 3 251 256
46. Y. Mori K. Tatematsu A. Koide S. Sugie T. Tanaka H. Mori Modification by curcumin of mutagenic activation of carcinogenic N-nitrosamines by extrahepatic cytochromes P-450 2B1 and 2E1 in rats Cancer sci. 2006 97 9 896 904
47. B. S. Reddy Y. Hirose R. Lubet V. Steele G. Kelloff S. Paulson K. Seibert C. V. Rao Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis Cancer Res. 2000 60 2 293 297
48. R. F. Jacoby K. Seibert C. E. Cole G. Kelloff R. A. Lubet The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis Cancer Res. 2000 60 18 5040 5044
49. C. H. Chiu M. F. McEntee J. Whelan Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis Cancer Res. 1997 57 19 4267 4273
50. S. K. Boolbol A. J. Dannenberg A. Chadburn C. Martucci X. J. Guo J. T. Ramonetti M. Abreu-Goris H. L. Newmark M. L. Lipkin J. J. DeCosse M. M. Bertagnolli Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis Cancer Res. 1996 56 11 2556 2560
51. R. Basha C. H. Baker U. T. Sankpal S. Ahmad S. Safe J. L. Abbruzzese M. Abdelrahim Therapeutic applications of NSAIDS in cancer: special emphasis on tolfenamic acid Front. Biosci., Scholar Ed. 3S 797 805
52. G. W. Chang P. C. Kam The physiological and pharmacological roles of cytochrome P450 isoenzymes Anaesthesia 1999 54 1 42 50
53. C. Cheung A. M. Yu J. M. Ward K. W. Krausz T. E. Akiyama L. Feigenbaum F. J. Gonzalez The cyp2e1-humanized transgenic mouse: role of cyp2e1 in acetaminophen hepatotoxicity Drug Metab. Dispos. 2005 33 3 449 457
54. D. T. Trafalis E. S. Panteli A. Grivas C. Tsigris P. N. Karamanakos CYP2E1 and risk of chemically mediated cancers Expert Opin. Drug Metab. Toxicol. 2010 6 3 307 319
55. N. P. Lang M. A. Butler J. Massengill M. Lawson R. C. Stotts M. Hauer-Jensen F. F. Kadlubar Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps Cancer Epidemiol., Biomarkers Prev. 1994 3 8 675 682
56. S. Kimura M. Kawabe A. Yu H. Morishima P. Fernandez-Salguero G. J. Hammons J. M. Ward F. F. Kadlubar F. J. Gonzalez Carcinogenesis of the food mutagen PhIP in mice is independent of CYP1A2 Carcinogenesis 2003 24 3 583 587
57. T. Shimada H. Yamazaki M. Mimura Y. Inui F. P. Guengerich Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians J. Pharmacol. Exp. Ther. 1994 270 1 414 423
58. C. Keshava E. C. McCanlies A. Weston CYP3A4 polymorphisms-potential risk factors for breast and prostate cancer: a HuGE review Am. J. Epidemiol. 2004 160 9 825 841
59. J. A. Goldstein S. M. de Morais Biochemistry and molecular biology of the human CYP2C subfamily Pharmacogenetics 1994 4 6 285 299
60. U. Yasar E. Eliasson M. L. Dahl Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk Carcinogenesis 2002 23 4 665
61. C. S. Yang J. S. Yoo H. Ishizaki J. Y. Hong Cytochrome P450IIE1: roles in nitrosamine metabolism and mechanisms of regulation Drug Metab. Rev. 1990 22 2-3 147 159
62. M. J. Coon X. X. Ding S. J. Pernecky A. D. Vaz Cytochrome P450: progress and predictions FASEB J. 1992 6 2 669 673
63. D. R. Koop Oxidative and reductive metabolism by cytochrome P450 2E1 FASEB J. 1992 6 2 724 730
64. L. F. Pinto E. Moraes R. M. Albano M. C. Silva W. Godoy T. Glisovic M. A. Lang Rat oesophageal cytochrome P450 (CYP) monooxygenase system: comparison to the liver and relevance in N-nitrosodiethylamine carcinogenesis Carcinogenesis 2001 22 11 1877 1883
65. D. R. Koop Oxidative and reductive metabolism by cytochrome P450 2E1 FASEB J. 1992 6 2 724 730
66. P. N. Karamanakos D. T. Trafalis G. D. Geromichalos P. Pappas P. Harkitis M. Konstandi M. Marselos Inhibition of rat hepatic CYP2E1 by quinacrine: molecular modeling investigation and effects on 4-(methyl nitrosamino)-1-(3- pyridyl)-1-butanone (NNK)-induced mutagenicity Arch. Toxicol. 2009 83 6 571 580
67. G. Millonig Y. Wang N. Homann F. Bernhardt H. Qin S. Mueller H. Bartsch H. K. Seitz Ethanol-mediated carcinogenesis in the human esophagus implicates CYP2E1 induction and the generation of carcinogenic DNA-lesions Int. J. Cancer 2011 128 3 533 540
68. N. K. Zgheib Z. Mitri E. Geryess P. Noutsi Cytochrome P4502E1 (CYP2E1) genetic polymorphisms in a Lebanese population: frequency distribution and association with morbid diseases Genet. Test. Mol. Biomarkers 2010 14 3 393 397
69. Y. Niu H. Yuan W. Leng Y. Pang N. Gu N. Chen CYP2E1 Rsa I/Pst I polymorphism and esophageal cancer risk: a meta-analysis based on 1,088 cases and 2,238 controls Med. Oncol. (N. Y., NY, U. S.) 2011 28 1 182 187
70. M. Wu J. K. Zhao Z. F. Zhang R. Q. Han J. Yang J. Y. Zhou X. S. Wang X. F. Zhang A. M. Liu P. van't Veer F. J. Kok E. Kampman Smoking and alcohol drinking increased the risk of esophageal cancer among Chinese men but not women in a high-risk population Cancer, Causes Control, Pap. Symp. 2011 22 4 649 657
71. F. E. Thorngate R. Raghow H. G. Wilcox C. S. Werner M. Heimberg M. B. Elam Insulin promotes the biosynthesis and secretion of apolipoprotein B-48 by altering apolipoprotein B mRNA editing Proc. Natl. Acad. Sci. U. S. A. 1994 91 12 5392 5396
72. C. R. Yellaturu X. Deng L. M. Cagen H. G. Wilcox C. M. Mansbach, 2nd S. A. Siddiqi E. A. Park R. Raghow M. B. Elam Insulin enhances post-translational processing of nascent SREBP-1c by promoting its phosphorylation and association with COPII vesicles J. Biol. Chem. 2009 284 12 7518 7532
73. S. A. Siddiqi VLDL exits from the endoplasmic reticulum in a specialized vesicle, the VLDL transport vesicle, in rat primary hepatocytes Biochem. J. 2008 413 2 333 342
74. S. Siddiqi A. M. Mani S. A. Siddiqi The identification of the SNARE complex required for the fusion of VLDL-transport vesicle with hepatic cis-Golgi Biochem. J. 2010 429 2 391 401
75. S. A. Siddiqi J. Mahan S. Siddiqi F. S. Gorelick C. M. Mansbach, 2nd Vesicle-associated membrane protein 7 is expressed in intestinal ER J. Cell Sci. 2006 119 Pt 5 943 950
76. I. Neeli S. A. Siddiqi S. Siddiqi J. Mahan W. S. Lagakos B. Binas T. Gheyi J. Storch C. M. Mansbach, 2nd Liver fatty acid-binding protein initiates budding of pre-chylomicron transport vesicles from intestinal endoplasmic reticulum J. Biol. Chem. 2007 282 25 17974 17984